AN-2728 is primarily investigated for its potential as a topical anti-inflammatory agent, particularly in the treatment of skin conditions such as atopic dermatitis and psoriasis. It functions as a selective inhibitor of phosphodiesterase 4 (PDE4), an enzyme involved in the degradation of cyclic AMP, leading to reduced levels of pro-inflammatory cytokines. By inhibiting PDE4, AN-2728 helps modulate the immune response in the skin, decreasing inflammation, redness, and irritation without the use of steroids. Its development focuses on providing a non-steroidal alternative for long-term management of chronic inflammatory skin diseases, with improved safety and tolerability profiles compared to traditional corticosteroids. Research has shown promising results in preclinical models, supporting its use in dermatological formulations aimed at sensitive or pediatric populations.